prenatal testing (NIPT) and preimplantation genetic diagnosis (PGD); (iii) newborn screening; (iv) whole-genome and wholeexome sequencing for suspected rare disease; (v) oncology and tumor profiling; (vi) risk assessment for and diagnosis of other common diseases and conditions and (vii) pharmacogenomics.
We identified 43 companies and academic laboratories that offer genetic testing services through a CLIA-certified laboratory (Supplementary Table 1 ). Figure 1 shows the breakdown of clinical offerings among the 43 providers. Among the most common clinical offerings, 70% (n = 30) of providers offer oncology-related testing, including tumor profiling, and 56% (n = 24) provide risk assessment and/or diagnosis of other common and chronic diseases and conditions, not including oncologyrelated tests. One-third of those offering oncology-related testing (n = 10) do not offer any other type of testing (Fig. 1) . The remaining two-thirds of oncology-related test providers also offer testing services for common and chronic diseases.
Three companies provide services in all seven clinical segments; 40% (n = 17) of providers are operating in maternal and perinatal NGS services (preconception, prenatal, and newborn screening), and approximately half (n = 8) are operating only in those clinical segments (Fig. 1) . Of the companies and academic institutions that we identified, none are providing pharmocogenomic testing only. Similarly, only one is focused solely on whole-genome and whole-exome sequencing for rare disease-providers of this type of clinical testing usually also offer testing for oncology and common and/or chronic diseases.
Many commentators support linking oversight of NGS-based testing to risk, and this is largely compatible with current and proposed regulatory frameworks. Under the statute that governs FDA regulation of medical devices, devices are classified on the basis of the controls necessary to
To the Editor:
The ability to sequence entire human genomes has been of clinical benefit in oncology and the diagnosis of rare diseases, and its application is expanding to other clinical domains 1 . Yet, in the words of the former US Food and Drug Administration (FDA) commissioner Margaret Hamburg and US National Institutes of Health (NIH) director Francis Collins, "even the most promising technologies cannot fully realize their potential if the relevant policy, legal, and regulatory issues are not adequately addressed" 2 . Currently, there is vigorous debate about how to develop effective regulatory and reimbursement policy for next-generation sequencing (NGS)-based clinical testing. Ongoing policy movement in these areas introduces challenges but also creates opportunities for stakeholders to influence the course of further policy development.
Recent events underline the degree to which regulatory policy remains a work in progress. In October 2014, the FDA issued a draft guidance document outlining a proposed framework for regulatory oversight of laboratory-developed tests (LDTs) 3 . The proposal, if finalized, would reverse a decades-old policy of enforcement discretion. As the majority of NGS-based tests for specific conditions have been developed as LDTs (only two have been submitted for FDA review as in vitro diagnostic test kits), FDA regulation of LDTs could have a major impact on the development of NGS-based testing.
Some commentators have expressed concern about the agency's capacity to address a rapidly evolving technology as well as the scope of its legal authority 4, 5 . The FDA and its defenders, arguing that the agency has the authority to support the policy shift, point to the increased complexity of newer tests. Specifically, they cite the need for regulatory attention to test characteristics, such as clinical validity, to complement the regulation of laboratory practice under the Clinical Laboratory Improvement Amendments (CLIA) and the regulation of medical practice under state laws 3 . To further support its position, FDA issued a report in November 2015, in advance of a US House Energy and Commerce Subcommittee on Health hearing, that features 20 case studies on the risks to patients of inaccurate, unregulated tests 6 . These risks include false negatives, which may result in patients being denied access to helpful therapies, and false positives, which could lead to harmful or unnecessary procedures. Even regulatory clearance (where legally required) does not necessarily address payers' desire for evidence of clinical utility and costeffectiveness. In the area of reimbursement, evidentiary standards and coverage policy vary across payers, and many existing approaches are inadequate to capture the full value of NGS 7 .
Understanding the features of the NGS industry as it develops is essential to adequately address policy issues and to fully realize the potential of clinical NGS. Our previous work showed that companies offering NGS services have disparate business models and offer a range of services, which, in turn, has policy implications 8 . Here we focus on the clinical applications of NGS technology. We map the clinical segmentation of NGS providers, focusing on the multiplicity of clinical applications of sequencing technology. Mapping the clinical segmentation of NGS providers and the distinctive constellation of risks and benefits for each clinical segment is important for developing more targeted and effective policy. To capture the clinical segmentation of NGS providers through a landscape analysis, we built on categories used in reimbursement, scientific and clinical contexts 1, 9 . We identified seven relevant categories with distinct regulatory and/or reimbursement implications: (i) preconception carrier screening; (ii) prenatal testing, including noninvasive Developing context-specific next-generation sequencing policy Newborn screening. The goal of newborn screening is to detect severe, rare conditions that can be treated early. As the cost of whole-genome sequencing declines, some have argued that newborn screening programs could benefit from NGS 16 . Newborn screening programs are mandated by all states and usually presume parental consent. If NGS were used in newborn screening, the benefits could include provide reasonable assurance of safety and effectiveness 10 . Class III devices are subject to the most stringent oversight, including premarket approval, and are either high-stakes or high-risk and lack information about the adequacy of controls. The two NGS-based cystic fibrosis kits cleared by the FDA as class II were determined to be substantially equivalent to kits already on the market and intended for expert use in conjunction with other laboratory and clinical information.
Preconception carrier screening. Of the entities that provide preconception carrier screening, only 9% provide this service exclusively. More than half (69%) also provide prenatal testing, with both clinical applications equally represented ( Fig. 1) .
The primary benefit of preconception carrier screening is to help prospective parents predict the chances of having a child with a Mendelian genetic disorder ( Table 1) . The American College of Obstetricians and Gynecologists recommends testing for people who have a family history of a genetic disorder or belong to an ethnic group that has a high rate of carriers of certain genetic disorders 11 . NGS-based testing, however, allows screening for a large number of conditions simultaneously, and it can provide information about conditions other than those covered by current screening guidelines. Whereas this may shed light on some new conditions and provide information that guides the health care of future parents, the concern is that expanded panels include conditions that vary in penetrance and presentation, including age of onset. Another concern is that preconception carrier screening may give prospective parents false confidence and lead them to refuse newborn screening 12 .
Prenatal testing. Prenatal testing includes an array of technologies. Of the providers surveyed, 30% provide at least one, if not a combination, of these technologies (Fig. 1) 14 .
NIPT may have the potential benefit of earlier detection without the risks associated with more invasive techniques, but NIPT has been shown to be limited, as compared with cytogenetic tests, by the number of 17 . From a policy point of view, states consider newborn screening programs by assessing the overall public health benefits. Therefore, the use of NGS for statebased programs could require a different level of clinical utility evidence than that for individual testing, because assessment would be made for the clinical benefits to the newborn population as a whole.
C O R R E S P O N D E N C E
Suspected rare disease. The number of market entrants in the rare disease segment is small compared with that for oncology (Fig. 1 ). Yet the literature suggests that recognition of clinical value in this segment is growing 1, 18 . This is also Oncology and tumor profiling. Oncology is adopting NGS technology rapidly, especially for tumor profiling, as demonstrated by the relatively large number of entrants in this space (Fig. 1) . Industry representatives have asserted that the innovation possible via LDTs under the FDA's long-standing policy of enforcement discretion has allowed correction of problems with existing oncology-related FDA-approved companion diagnostics 20 . At the same time, concerns about risks to patients are heightened in this area, because test results can be used to select therapy for life-threatening conditions 3, 6 . Furthermore, tumor profiling is among the most technically challenging clinical applications of NGS technology ( Table 1 ). In light of such concerns, the rush of providers into NGS-based testing in oncology signals peril (such as a proliferation of tests that makes assessment more challenging, entry of providers offering low-quality tests and inflation of claims to garner market share) as well as promise (such as the anticipated benefits of better matching of patients and tumors with therapy and identifying individuals at heightened risk of cancer faster and at lower cost). The key policy task is to develop an oversight system tailored to this clinical segment, where continuous innovation is beneficial, stakes are high and test providers may have varying capacities to an area where the impact of the rapid evolution of knowledge is striking 18 . The technical challenges associated with NGSbased testing for rare disease are primarily concentrated in the interpretive phase of the NGS clinical pipeline ( Table 1) . The FDA has already signaled continued enforcement discretion for use of NGS in the context of rare disease 3 . Optimally, payers would also adopt a flexible approach, recognizing that traditional approaches to demonstrating clinical utility that depend on specific treatment benefit in a population are not suited to diseases that affect few individuals with limited treatment options. The outcome may be simply the precise diagnosis of an untreatable condition, which could nonetheless end a tortuous diagnostic odyssey 19 . Many companies operating in this clinical space have academic affiliations and access to expertise in bioinformatics, medical genetics and genetic counseling, features that make these institutions good partners to develop alternatives to mitigate risk and establish benefit. Furthermore, as the clinical utility of NGS-based testing for rare disease is intrinsically tied to the availability of large data sets to aid with interpretation of results, the case is especially strong for tying coverage and reimbursement for rare disease testing to the deposition of information in public databases. 27 . The second consideration is that policymakers should review evidence concerning the full range of outcomes that affect patients and accommodate ongoing evidence creation. For example, payers often rely on regulators to assess safety and efficacy, but they may also seek evidence showing that the test has clinical utility or will lead to an improved clinical outcome before covering an intervention. Scholars have advocated for a broad concept of utility that includes utility over time, and personal utility, wherein information helps with nonmedical decision making or provides value in other ways (for example, by influencing reproductive planning or providing a long-sought diagnosis), in decisions about coverage and reimbursement 7, 19 . Furthermore, 'coverage with evidence development' might establish the feasibility of contingent coverage that does not require all the evidence up front. Payers are experimenting with such policies with an eye toward identifying situations in which there are viable alternatives to binary coverage choices.
An FDA discussion paper on NGS points to the broad and 'indication-blind' nature of NGS 28 . On the basis of our discussion above, we suggest that different clinical applications of NGS should be taken into account when tailoring policies to the clinical context. Some policy issues, such as generation and management of secondary findings, will cut across many clinical uses, but the risk-benefit considerations in carrier screening, newborn screening, oncology, pharmacogenomics and other clinical contexts will differ. Likewise, as professional societies have noted in their recommendations regarding riskbased classification of genetic tests, lack of transparency, especially in the area of variant interpretation, heightens risk. The taxonomy of clinical contexts for NGS can help guide decisions about regulation and reimbursement by helping distinguish context-specific risks and benefits. deliver high-quality, evidence-based results.
Consensus has yet to emerge on the best regulatory approach. However, given the high financial and clinical stakes, oncology is an area in which data sharing is critical, both to facilitate external validation and to rapidly and efficiently circulate information about problems. Payers and regulators may have a role in creating positive incentives (e.g., accelerated review processes for laboratories that share data or payment to cover sharing data) or negative incentives (e.g., coverage only for tests that can be independently verified with public data sets, certification of laboratories or professionals that requires data sharing or reimbursement contingent on data sharing). A recent report issued by the Green Park Collaborative, an initiative of the Center for Medical Technology Policy, proposes initial medical policy and medical coverage guidelines for NGS-based oncology testing and mentions several positive modes to incentivize data sharing 21 .
Risk assessment and diagnosis of common disease. Several companies and academic institutions are using NGS for risk assessment or diagnosis of common diseases (Fig. 1) . Examples include type 2 diabetes, coronary artery disease and hypertension ( Table 1) . Unlike Mendelian diseases, common, complex disorders can be influenced by many DNA variants, each with a relatively low predictive value. Because most common diseases are not single-gene disorders, researchers have relied primarily on population-based studies or genome-wide association studies (GWAS) to understand the underlying genetics. Such studies, however, require additional research to determine whether variants with a high statistical correlation are causal. Findings from GWAS typically confer low relative risk and therefore often have lower predictive power with unclear clinical utility 22 . Models to combine multiple markers into a cumulative risk score are often flawed and usually no better than evaluation of traditional risk factors, such as family history and ancestry 22 (Table 1) . Whereas common disease testing may have the benefit of earlier screening and identification of disease, it could also lead to interventions without established benefit. Although the overall risk is relatively low, payers should be cautious in covering testing whose clinical value has not been demonstrated.
Pharmacogenomic testing. Pharmacogenomic testing aims to use genetic variants to better understand and predict the effectiveness of a drug for a particular population. Potential benefits include avoidance of risks associated with ineffective therapeutics or of toxicity of therapeutics prescribed at standard doses ( Table 1) . The anticoagulant warfarin is often held up as an example, as variants in the genes CYP2C9 and VKORC1 can be used to determine the optimal starting dose 23 . However, chip-based testing for determining warfarin dosage and other pharmacogenomics indications has been on the market for more than a decade with weak uptake 24 . NGS is mainly a technological substitute that might produce the same information at similar or lower cost, but it might also help to identify pharmacogenomic diplotypes relevant to the indication. However, this type of test also has inherent risks; establishing the phenotype of a pharmocogenomic test requires exposure to a drug. On the other hand, pharmacogenomic testing could be folded into testing for other indications and might be preferred for the additional information about drug reactions it provides. Payers might thus have an incentive for the latter to minimize the cost of ineffective therapeutics.
Although not comprehensive, this discussion shows the importance of attending to the distinctive features of each category in policy debates related to NGS-based testing. Additionally, it brings to the fore two considerations that merit greater emphasis. The first is the value of transparency in assuring appropriate clinical integration of NGS technology. Both the College of American Pathologists and the ACMG have been open to FDA premarket review of LDTs involving methodologies that are not well understood or independently verifiable or for which full transparency is not possible, as well as for products and services developed under nontransparent business models 25, 26 . Also worth mentioning is the potential alignment with governmental initiatives beyond the FDA, such as the US Office of the National Coordinator for Health Information Technology's efforts to encourage use of electronic health records and facilitate data sharing, and the NIH's investment in resources such as the online platforms ClinGen and ClinVar to facilitate free access to and sharing of genomic data. The American Society of Clinical Oncology has also updated its policy on genetic and genomic testing for oncology and supports a larger role for FDA and "efforts to catalog and annotate all genomic variants and to create rigorously curated open-access
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To the Editor: Current assisted reproductive technology (ART), such as in vitro fertilization and intracytoplasmic sperm injection, depends on the premise that both partners produce fertile eggs or sperm (gametes). As yet, there is no ART treatment for individuals with few or no gametes, unless donor gametes are used. Ongoing research suggests that autologous female or male germ cells may be regenerated from somatic cells by controlling cell fate; if so, there is a possibility that ART might aid infertile couples and even same-sex couples in the future. Before such ART treatments using induced germ cells can be considered in the clinical context, however, a great many questions concerning the safety and efficacy of such procedures must be answered. Moreover, profound ethical and social concerns will arise if such induced germ cells are needlessly generated, cryopreserved and used for reproductive purposes in clinics without a definition of their appropriate roles in ART. As a response to the increasing feasibility of inducing germ cells from human pluripotent stem cells, we discuss below the current technical challenges to creating induced human germ cells and explore some of the ethical, legal and social issues associated with their use in clinical practice.
Recent work has shown that mouse oocytes as well as spermatozoa can be differentiated from induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) via primordial germ-cell-like cells (PGCLCs), resulting in the birth of healthy offspring 1, 2 . Furthermore, rapid advances have also been made on human germ-cell induction research, including the generation
